Skip to content

ASTRUM-006 and the changing landscape of perioperative therapy for gastric cancer.

Oct 2026 · i Medicina · Vol 7 10, pp. 101302 · 0 citations · 8 references
Medicine

Abstract

ASTRUM-006 provides phase 3 evidence that perioperative immune checkpoint inhibition improves event-free survival with Asian SOX-based chemotherapy in PD-L1-positive gastric cancer. Its postoperative chemotherapy-sparing strategy is attractive, although unmasking, event adjudication, and non-R0 or occult metastatic disease warrant consideration. The study nevertheless broadens the perioperative treatment framework and provides an important platform for refining patient selection and postoperative treatment intensity.

View source

Similar papers

Review Sep 2026

Pancreatic ductal adenocarcinoma: Clinical trials to watch.

The treatment of PDAC is transitioning from uniform cytotoxic chemotherapy toward precision strategies guided by molecular identity and disease stage, and seven trials addressing these dimensions may collectively redefine PDAC treatment.

V. Groot, I. Molenaar, G. Cirkel et al. · 0 citations
Open access Oct 2026

Patients gain potential options for treatment of advanced NSCLC

Trials show that ivonescimab combined with chemotherapy improved overall survival, and sunvozertinib improved progression‐free survival, and ivonescimab combined with chemotherapy improved overall survival.

Leah Lawrence · 0 citations
Open access Sep 2026

PD‐1 Inhibitor (Sintilimab) Combined With Chemotherapy as Neoadjuvant Therapy in Advanced Ovarian Cancer: A Case Report

In a patient with advanced ovarian cancer showing limited response to paclitaxel–carboplatin, adding sintilimab was associated with R0 cytoreduction and sustained disease‐free status during olaparib–bevacizumab maintenance. This case provides a rationale for further investigation of PD‐1 blockade as neoadjuvant therapy...

Zhen-Yan Wang, Yan Wang · 1 citation
Open access Oct 2026

Survival Outcomes With Lu-177 PSMA by Treatment Line and Taxane Sequencing in Prostate Cancer

This cohort study examines time to next treatment and overall survival associated with initiation of lutetium Lu 177 vipivotide tetraxetan (Lu-177) prostate-specific membrane antigen (PSMA) among US patients with metastatic androgen pathway modulator–resistant prostate cancer.

Varun Nandakumar, Y. Jo, M. Ostrowski et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.